Phibro Animal Health (NASDAQ:PAHC) Lowered to Buy Rating by StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday.

A number of other brokerages also recently weighed in on PAHC. Morgan Stanley increased their price objective on shares of Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Barclays increased their price target on Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.50.

Phibro Animal Health Stock Performance

PAHC stock opened at $23.69 on Thursday. The stock has a market capitalization of $959.45 million, a PE ratio of 55.09, a price-to-earnings-growth ratio of 0.56 and a beta of 0.52. The stock’s 50 day simple moving average is $21.89 and its 200 day simple moving average is $21.63. Phibro Animal Health has a 12-month low of $10.03 and a 12-month high of $25.98. The company has a current ratio of 3.23, a quick ratio of 1.69 and a debt-to-equity ratio of 1.81.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.40 by $0.14. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. As a group, research analysts forecast that Phibro Animal Health will post 1.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its holdings in Phibro Animal Health by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock worth $11,430,000 after purchasing an additional 27,201 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Phibro Animal Health by 8.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 290,656 shares of the company’s stock worth $6,104,000 after buying an additional 22,263 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Phibro Animal Health by 2.9% during the 4th quarter. Bank of New York Mellon Corp now owns 272,632 shares of the company’s stock valued at $5,725,000 after buying an additional 7,747 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Phibro Animal Health by 116.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company’s stock valued at $4,330,000 after acquiring an additional 103,491 shares during the period. Finally, Segall Bryant & Hamill LLC increased its holdings in Phibro Animal Health by 1.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 174,569 shares of the company’s stock worth $3,931,000 after acquiring an additional 2,971 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.